



## **UBS Global Life Sciences Conference to Webcast Alkermes' Corporate Presentation**

September 21, 2005

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sept. 21, 2005--Alkermes, Inc. (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live by UBS on Wednesday, September 28, 2005 at 2:00 p.m. EDT. The presentation will be webcast from The Grand Hyatt Hotel in New York and may be accessed under the investor relation's tab at [www.alkermes.com](http://www.alkermes.com). The presentation will be archived for 14 days.

Alkermes, Inc. is a pharmaceutical company that develops products based on sophisticated drug delivery technologies to enhance therapeutic outcomes in major diseases. The Company's lead commercial product, RISPERDAL CONSTA(R) ((risperidone) long-acting injection), is the first and only long-acting atypical antipsychotic medication approved for use in schizophrenia, and is marketed worldwide by Janssen-Cilag ("Janssen"), a wholly owned subsidiary of Johnson & Johnson. The Company's lead proprietary product candidate, VIVITREX(R) (naltrexone long-acting injection), is being developed as a once-monthly injection for the treatment of alcohol dependence. The Company has a pipeline of extended-release injectable products and pulmonary drug products based on its proprietary technology and expertise. Alkermes' product development strategy is twofold: the Company partners its proprietary technology systems and drug delivery expertise with several of the world's finest pharmaceutical companies and it also develops novel, proprietary drug candidates for its own account. The Company's headquarters are in Cambridge, Massachusetts, and it operates research and manufacturing facilities in Massachusetts and Ohio.

CONTACT: Alkermes, Inc.  
Debra Koufos  
Associate, Corporate Communications  
617-583-6220

SOURCE: Alkermes, Inc.